sulfamethoxazole + hydroxyurea + azacytidine + cytarabine + thioguanine

**Sulfamethoxazole + hydroxyurea + azacytidine + cytarabine + thioguanine** is a five-drug combination without a standardized brand name or protocol identifier in clinical use. **Sulfamethoxazole**, a sulfonamide antibiotic, inhibits bacterial folate synthesis by competitively inhibiting dihydropteroate synthase. **Hydroxyurea**, an antimetabolite, inhibits ribonucleotide reductase, disrupting DNA synthesis and elevating fetal hemoglobin in sickle cell disease. **Azacytidine**, a hypomethylating agent (cytidine nucleoside analog), incorporates into RNA and DNA, inhibiting DNA methyltransferases to reactivate silenced genes and induce differentiation/apoptosis in myeloid cells. **Cytarabine**, a pyrimidine analog, inhibits DNA polymerase after activation to cytarabine triphosphate, causing chain termination primarily in S-phase cells. **Thioguanine**, a purine analog, is converted to thioguanine nucleotides that incorporate into DNA/RNA, disrupting nucleic acid synthesis. This combination merges antimicrobial prophylaxis (sulfamethoxazole) with intensive antineoplastic activity targeting DNA metabolism, likely for high-risk hematologic malignancies like acute myeloid leukemia (AML) in immunosuppressed patients, though no specific trial or approval exists for this exact regimen.